Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Status:	Completed
Conditions:	Skin Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	11/30/2013
Start Date:	November 2007
End Date:	July 2013
Contact:	Lucy Prasad
Email:	lprasad@talontx.com
Phone:	650-228-5014

A Phase 2 Study of Marqibo in Patients With Metastatic Uveal Melanoma

Marqibo (liposomal vincristine) is a form of vincristine preparation. Vincristine is
designed to interfere with the multiplication of cancer cells, which may slow or stop their
growing and spreading throughout the body. This may cause the cancer cells to die.
Liposomal vincristine is formed when vincristine is placed inside of oil droplets called
liposomes, which may help to improve the delivery of drug to the tumor site. The liposomal
formulation results in a slow, steady release of vincristine in the tumor metastasis,
exposing the cancer cells to vincristine continuously.

The goal of this clinical research study is to learn if Marqibo (liposomal vincristine) can
help to control metastatic uveal melanoma. The safety of liposomal vincristine will also be
studied.

Approximately 50 patients will take part in this study.

Inclusion Criteria:

- Uveal melanoma with histologic or cytologic confirmation of metastatic disease.

- One unidimensionally measurable lesion. If this is a cutaneous lesion it must be at
least 10 mm by caliper measure. If it is a visceral or nodal or soft tissue lesion,
it must be >20 mm with conventional techniques or >10 mm with spiral CT scan. Bone
lesions are not considered measurable.

- Must not have received any prior systemic chemotherapy, immunotherapy, vaccine or
hepatic arterial chemotherapy for metastatic disease.

- Adequate liver, renal, and bone marrow function.

- Zubrod performance status of 0-2.

- Sign an informed consent form.

Exclusion Criteria:

- Major surgery within 4 weeks of enrollment.

- Advanced symptomatic central nervous system (CNS) involvement by melanoma and those
on phenytoin or requiring steroids for brain metastases, spinal cord compression, or
meningeal "carcinomatosis".

- History of neurological disorders unrelated to chemotherapy (including familial
neurological diseases and acquired demyelinating disorders).

- Grade 2 or greater sensory, motor and/or autonomic neuropathy at screening from any
cause.

- Receiving treatment with drugs known to inhibit or induce hepatic drug metabolism by
cytochrome P450-3A4 isoenzymes and/or P-glycoprotein within 1 week of study
enrollment.

We found this trial at

sites

University of Colorado, Denver

Denver, Colorado 80045

from

Denver, CO